Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib Continuation in NSCLC with Brain-Only Progression
NCT01130779Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Aug 2009
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01130779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01130779.